Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Bevan, JS; Atkin, SL; Atkinson, AB; Bouloux, PM; Hanna, F; Harris, PE; James, RA; McConnell, M; Roberts, GA; Scanlon, MF; Stewart, PM; Teasdale, E; Turner, HE; Wass, JA; Wardlaw, JM

Abstract:

Conventional surgery and radiotherapy for acromegaly have limitations. There are few data on the use of the somatostatin analog octreotide (Oct) as primary medical therapy. An open prospective study of 27 patients with newly diagnosed acromegaly was conducted in nine endocrine centers in the United Kingdom. Twenty patients had macroadenomas, and 7 had microadenomas. For the first 24 wk (phase 1), patients received sc Oct in an initial dose of 100 microg, 3 times daily, increased to 200 micro ...

Expand abstract

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Bevan, J. S., Atkin, S. L., Atkinson, A. B., Bouloux, P. M., Hanna, F., Harris, P. E., James, R. A., McConnell, M., Roberts, G. A., Scanlon, M. F., Stewart, P. M., Teasdale, E., Turner, H. E., Wass, J. A., & Wardlaw, J. M. (2002). Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. The Journal of Clinical Endocrinology and Metabolism, 87(10), 4554–4563.

MLA Style

Bevan, J. S., et al. “Primary Medical Therapy for Acromegaly: an Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-like Growth Factor-I, and Tumor Size.” The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 10, The Journal of clinical endocrinology and metabolism, 2002, pp. 4554–63.

Chicago Style

Bevan, JS, SL Atkin, AB Atkinson, PM Bouloux, F Hanna, PE Harris, RA James, et al. 2002. “Primary Medical Therapy for Acromegaly: an Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-like Growth Factor-I, and Tumor Size.” The Journal of Clinical Endocrinology and Metabolism 87 (10): 4554–63.
Tweet
Print